Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Management and Outcome of Venous Thrombosis in Patients with Myeloproliferative Neoplasms: Data from the Israeli MPN Working Group

Management and Outcome of Venous Thrombosis in Patients with Myeloproliferative Neoplasms: Data... The BCR-ABL-negative myeloproliferative neoplasms (MPN) are associated with high incidence of venous thrombosis and a significant rate of recurrent events, but there is no consensus regarding their management. In this retrospective study, we analyzed 96 patients with MPN-related venous thrombosis. The index venous thrombosis occurred at a median age of 58 years (IQR 37–71), with 58% of the events involving unusual sites. Patients who were on antiplatelet agents at the time of index thrombosis tended to be older than patients who were not receiving antiplatelets at the time of index thrombosis. The majority of index thromboses occurring after the diagnosis of MPN had uncontrolled blood counts at the time of event and were not receiving antithrombotic agents. Following the thrombotic episode, 75% of patients received long-term anticoagulation. At a median follow-up of 3.4 years, the recurrence rate was 14%. Thrombophilia was significantly more prevalent among patients with recurrent thrombosis compared to patients without recurrence (p < 0.01). Patients who developed a recurrent event early were more likely to have thrombophilia (either inherited or antiphospholipid antibodies), and controlled blood counts, and were likely to receive anticoagulation at the time of recurrence compared to patients with later recurrences. Thrombophilia may contribute to venous thrombosis recurrence, especially early after the index venous thrombosis. Suboptimal anticoagulation and blood count control are factors associated with late venous thrombosis recurrence. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Haematologica Karger

Management and Outcome of Venous Thrombosis in Patients with Myeloproliferative Neoplasms: Data from the Israeli MPN Working Group

Download PDF
8 pages

Loading next page...
 
/lp/karger/management-and-outcome-of-venous-thrombosis-in-patients-with-1sTx4XbeJ2

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Karger
Copyright
© 2020 S. Karger AG, Basel
ISSN
0001-5792
eISSN
1421-9662
DOI
10.1159/000511426
Publisher site
See Article on Publisher Site

Abstract

The BCR-ABL-negative myeloproliferative neoplasms (MPN) are associated with high incidence of venous thrombosis and a significant rate of recurrent events, but there is no consensus regarding their management. In this retrospective study, we analyzed 96 patients with MPN-related venous thrombosis. The index venous thrombosis occurred at a median age of 58 years (IQR 37–71), with 58% of the events involving unusual sites. Patients who were on antiplatelet agents at the time of index thrombosis tended to be older than patients who were not receiving antiplatelets at the time of index thrombosis. The majority of index thromboses occurring after the diagnosis of MPN had uncontrolled blood counts at the time of event and were not receiving antithrombotic agents. Following the thrombotic episode, 75% of patients received long-term anticoagulation. At a median follow-up of 3.4 years, the recurrence rate was 14%. Thrombophilia was significantly more prevalent among patients with recurrent thrombosis compared to patients without recurrence (p < 0.01). Patients who developed a recurrent event early were more likely to have thrombophilia (either inherited or antiphospholipid antibodies), and controlled blood counts, and were likely to receive anticoagulation at the time of recurrence compared to patients with later recurrences. Thrombophilia may contribute to venous thrombosis recurrence, especially early after the index venous thrombosis. Suboptimal anticoagulation and blood count control are factors associated with late venous thrombosis recurrence.

Journal

Acta Haematologica – Karger

Published: Jul 1, 2021

Keywords: Venous thrombosis; Myeloproliferative neoplasms; JAK2V617F; Thrombophilia

References

  • Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms
    Ball, S; Thein, KZ; Maiti, A; Nugent, K
  • Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis
    Smalberg, JH; Arends, LR; Valla, DC; Kiladjian, J-J; Janssen, HL; Leebeek, FW
  • Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study
    Martinelli, I; De Stefano, V; Carobbio, A; Randi, ML; Santarossa, C; Rambaldi, A
  • Splanchnic vein thrombosis in the myeloproliferative neoplasms
    Akpan, IJ; Stein, BL
  • Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study
    Hultcrantz, M; Bjӧrkholm, M; Dickman, PW; Landgren, O; Derolf, ÅR; Kristinsson, SY
  • Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera
    Landolfi, R; Di Gennaro, L; Barbui, T; De Stefano, V; Finazzi, G; Marfisi, R
  • Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments
    De Stefano, V; Za, T; Rossi, E; Vannucchi, AM; Ruggeri, M; Elli, E
  • Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked
    Elliott, MA; Pardanani, A; Lasho, TL; Schwager, SM; Tefferi, A
  • Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia
    Hernández-Boluda, JC; Arellano-Rodrigo, E; Cervantes, F; Alvarez-Larrán, A; Gómez, M; Barba, P
  • High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists
    De Stefano, V; Ruggeri, M; Cervantes, F; Alvarez-Larrán, A; Iurlo, A; Randi, M
  • Efficacy and safety of low-dose aspirin in polycythemia vera
    Landolfi, R; Marchioli, R; Kutti, J; Gisslinger, H; Tognoni, G; Patrono, C
  • Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖGHO) and Society of Thrombosis and Haemostasis Research (GTH eV)
    Kreher, S; Ochsenreither, S; Trappe, RU; Pabinger, I; Bergmann, F; Petrides, PE
  • Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
    Barbui, T; Tefferi, A; Vannucchi, AM; Passamonti, F; Silver, RT; Hoffman, R
  • Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases
    De Stefano, V; Rossi, E; Carobbio, A; Ghirardi, A; Betti, S; Finazzi, G
  • Treatment of thromboembolic events coincident with the diagnosis of myeloproliferative neoplasms: a physician survey
    Ellis, MH; Lavi, N; Vannucchi, A; Harrison, C
  • High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation
    Wille, K; Sadjadian, P; Becker, T; Kolatzki, V; Horstmann, A; Fuchs, C
  • Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study)
    Le Calloch, R; Lacut, K; Le Gall-Ianotto, C; Nowak, E; Abiven, M; Tempescul, A
  • Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis
    Harrison, C; Donohoe, S; Carr, P; Dave, M; Mackie, I; Machin, S
  • Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia
    Ruggeri, M; Gisslinger, H; Tosetto, A; Rintelen, C; Mannhalter, C; Pabinger, I
  • Mutation of the prothrombin gene and thrombotic events in patients with polycythemia vera or essential thrombocythemia: a cohort study
    Gisslinger, H; Müllner, M; Pabinger, I; Heis-Vahidi-Fard, N; Gisslinger, B; Brichta, A
  • Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with myeloproliferative disorders
    Tevet, M; Ionescu, R; Dragan, C; LUPU, AR
  • Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients
    De Stefano, V; Vannucchi, AM; Ruggeri, M; Cervantes, F; Alvarez-Larrán, A; Iurlo, A